Lung cancer DNA methylation molecular markers and application thereof in preparation of kit for early diagnosis of lung cancer

Abstract

The invention discloses a group of DNA methylation molecular markers for lung cancer and application of the DNA methylation molecular markers in preparation of a kit for early diagnosis of lung cancer. The marker is obtained through methylation of 20 gene sequences of CDO1, SOX17, TCF21, TRIM58, ITGA9, CYYR1, CLEC14A, SLIT2, ZNF677, IRX2, ACVRL1, OSR1, ADCY8, GALNT13, HSPB6, IRX1, ITGA5, PCDH17, TBX5 and TTEX1D1. Eight of the gene sequences are methylated fingerprint genes newly found in lung cancer, and the methylated fingerprint genes comprise ADCY8, GALNT13, HSPB6, IRX1, ITGA5, PCDH17, TBX5 and TTEX1D1. On the basis of the markers, a mathematical model for lung cancer diagnosis is constructed; and the model is high in sensitivity and good in specificity, the AUC can reach 0.998, and the diagnosis effect is good. The invention also discloses a method for detecting the DNA methylation marker. The DNA methylation molecular marker disclosed by the invention has good diagnostic index characteristics, can be effectively used for lung cancer diagnosis, and has relatively high clinical use and popularization values.

Description

technical field [0001] The invention relates to the technical field of biological detection, in particular to a group of DNA methylation molecular markers of lung cancer and their application in preparing a diagnostic kit for lung cancer. Background technique [0002] Lung cancer is one of the biggest malignant tumors that threaten people's health and life. In 2020, about 1.8 million people will die of lung cancer in the world. . Lung cancer is mainly divided into two types: non-small cell lung cancer (NSCLC) and small cell lung cancer. NSCLC is the most important type, accounting for more than 80% of all lung cancers. NSCLC mainly includes two subtypes, adenocarcinoma and squamous cell carcinoma. Adenocarcinoma accounts for 40% of all lung cancer types and about 55% of NSCLC. Non-small cell lung cancer proliferates and invades slower, so it is more difficult to be detected and diagnosed. When most patients with non-small cell lung cancer are diagnosed, they have alread...

AI Technical Summary

Problems solved by technology

Non-small cell lung cancer proliferates and invades more slowly, making it less likely to be detected and diagnosed

When most patients with non-small cell lung cancer are diagnosed, they have already developed into the middle and advanced stage of the tumor, missing the best time for treatment

Images